UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006429
Receipt number R000007629
Scientific Title Study the efficacy and safety of fentanyl patches on QOL/ADL in patients with chronic pain
Date of disclosure of the study information 2011/12/01
Last modified on 2014/04/01 16:36:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study the efficacy and safety of fentanyl patches on QOL/ADL in patients with chronic pain

Acronym

Study of efficacy and safety of fentanyl patches for chronic pain.

Scientific Title

Study the efficacy and safety of fentanyl patches on QOL/ADL in patients with chronic pain

Scientific Title:Acronym

Study of efficacy and safety of fentanyl patches for chronic pain.

Region

Japan


Condition

Condition

patients with chronic pain

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the efficacy and safety of fentanyl patch on QOL/ADL in patients with chronic pain.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

VAS: Visual Analogue Scale

Key secondary outcomes

SF-36
Patient satisfaction (at the end of the test is performed out of 5)
Adverse event


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Durotep MT patch
6 weeks
2.1mg~16.8mg

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients over 20 years of age
Written informed conscent to receive this therapy
Visual Analog Scale of pain intensity felt in daily life of an average in patients over 40mm

Key exclusion criteria

Patients with hypersensitivity to opioids
Patients with a history of opioid abuse
Patients with respiratory dysfunction such as chronic lung disease
Patients with asthma
Patients with severe cardiac dysfunction
Patients with severe liver and renal dysfunction
Intracranial hypertension, patients with impaired consciousness
Eczema at the site of drug patch testing, patients with atopic dermatitis, etc.
Patients with fever above 40 degree was observed
Pregnant women, patients might have been pregnant or nursing mothers
Within two days before starting the test, patients who are scheduled to be administered to patients receiving an opioid receptor antagonist such as pentazocine or buprenorphine.

Target sample size

5


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toru Hasegawa

Organization

Kawasaki Medical School

Division name

Department of Orthopedics, Traumatology and Spine Surgery

Zip code


Address

577 Matsushima Kurashiki city,Okayama

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Toru Hasegawa

Organization

Kawasaki Medical School

Division name

Department of Orthopedics, Traumatology and Spine Surgery

Zip code


Address

577 Matsushima Kurashiki city,Okayama

TEL


Homepage URL


Email



Sponsor or person

Institute

Kawasaki Medical School,Department of Orthopedics, Traumatology and Spine Surgery

Institute

Department

Personal name



Funding Source

Organization

non

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 12 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 09 Month 28 Day

Last modified on

2014 Year 04 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007629


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name